18 /100
LOW RISK
Score updated Jul 13, 2026

ORMP — Oramed Pharmaceuticals Inc. Dilution Risk Tracker

Track ORMP dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ORMP — Get alerts when the score changes →

As of July 13, 2026, Oramed Pharmaceuticals Inc. (ORMP) has a DilutionWatch DilutionScore of 18/100, rated LOW dilution risk. Oramed Pharmaceuticals Inc. has a market capitalization of $162.48M, 40.93M shares outstanding, 72 institutional holders tracked. Key dilution vectors include 20.0K outstanding warrants, approximately 63 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
0
📊 Float Risk
25
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for ORMP.
🔔 Track ORMP — Get forecast alerts →

💹 Market Data

Market Cap$162.48M
Shares Outstanding40.93M
Float28.57M
Cash$70.66M
Debt$106.58M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↓ 26.1% shares (2026Q1 vs prior)
72 institutional holders · 1.18M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 528.1K shares
#2 ARMISTICE CAPITAL, LLC 297.7K shares
#3 BlackRock, Inc. 102.8K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest877.8K
Days to Cover1.2
% of Float3.1%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Aug 31, 2013
4 INSIDER TRANSACTION Mar 31, 2026
4 INSIDER TRANSACTION Mar 31, 2026
8-K 8K EVENT Mar 31, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for ORMP Shareholders

Oramed Pharmaceuticals Inc. (ORMP) has a DilutionScore of 18/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for ORMP shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for ORMP in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for ORMP alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track ORMP Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ORMP — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for ORMP
📊 ORMP FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ORMP Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.